Home » Stocks » CHGCY

Chugai Pharmaceutical Co., Ltd. (CHGCY)

Stock Price: $23.16 USD 0.80 (3.58%)
Updated November 27, 12:55 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 12.96B
Revenue (ttm) 753.85B
Net Income (ttm) 202.56B
Shares Out 559.69M
EPS (ttm) 2.85
PE Ratio 8.13
Forward PE 28.49
Dividend $0.24
Dividend Yield 1.04%

Stock Quote

Trading Day November 27
Last Price $23.16
Previous Close $22.36
Change ($) 0.80
Change (%) 3.58%
Day's Open 22.57
Day's Range 22.57 - 23.97
Day's Volume 17,644
52-Week Range 12.853 - 28.43

More Stats

Market Cap 12.96B
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date Jul 6, 2020
Shares Outstanding 559.69M
Float n/a
EPS (basic) n/a
EPS (diluted) 2.85
FCF / Share n/a
Dividend $0.24
Dividend Yield 1.04%
Earnings Yield 12.31%
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 0.61
PE Ratio 8.13
Forward PE 28.49
P/FCF Ratio n/a
PS Ratio 0.02
PB Ratio 8.16
Revenue 753.85B
Operating Income n/a
Net Income 202.56B
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin 55.73%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA 16.02%
ROE 23.31%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Chugai Pharmaceutical Co., Ltd.
Country Japan
Employees 7,394
CEO Tatsuro Kosaka

Stock Information

Ticker Symbol CHGCY
Stock Exchange US OTC
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier OTCMKTS: CHGCY


Chugai Pharmaceutical Company, together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.